Literature DB >> 31659015

Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.

Kea Martin1, Ratiba Touil1, Yeter Kolb1, Grozdan Cvijetic1, Kiichi Murakami2, Laura Israel1, Fernanda Duraes1, David Buffet1, Anton Glück1, Satoru Niwa1, Marc Bigaud1, Tobias Junt1, Natasa Zamurovic1, Philip Smith1, Kathy D McCoy3, Pamela S Ohashi2,4, Frédéric Bornancin1, Thomas Calzascia5.   

Abstract

The paracaspase Malt1 is a key regulator of canonical NF-κB activation downstream of multiple receptors in both immune and nonimmune cells. Genetic disruption of Malt1 protease function in mice and MALT1 mutations in humans results in reduced regulatory T cells and a progressive multiorgan inflammatory pathology. In this study, we evaluated the altered immune homeostasis and autoimmune disease in Malt1 protease-deficient (Malt1PD) mice and the Ags driving disease manifestations. Our data indicate that B cell activation and IgG1/IgE production is triggered by microbial and dietary Ags preferentially in lymphoid organs draining mucosal barriers, likely as a result of dysregulated mucosal immune homeostasis. Conversely, the disease was driven by a polyclonal T cell population directed against self-antigens. Characterization of the Malt1PD T cell compartment revealed expansion of T effector memory cells and concomitant loss of a CD4+ T cell population that phenotypically resembles anergic T cells. Therefore, we propose that the compromised regulatory T cell compartment in Malt1PD animals prevents the efficient maintenance of anergy and supports the progressive expansion of pathogenic, IFN-γ-producing T cells. Overall, our data revealed a crucial role of the Malt1 protease for the maintenance of intestinal and systemic immune homeostasis, which might provide insights into the mechanisms underlying IPEX-related diseases associated with mutations in MALT1.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31659015      PMCID: PMC6859376          DOI: 10.4049/jimmunol.1900327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

1.  The pathway of antigen uptake and processing dictates MHC class II-mediated B cell survival and activation.

Authors:  Toufic O Nashar; James R Drake
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

2.  The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial autoantibodies.

Authors:  Masanobu Tsuda; Troy R Torgerson; Carlo Selmi; Eleonora Gambineri; Magda Carneiro-Sampaio; Sara Ciullini Mannurita; Patrick S C Leung; Gary L Norman; M Eric Gershwin
Journal:  J Autoimmun       Date:  2010-07-22       Impact factor: 7.094

3.  Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria.

Authors:  Usriansyah Hadis; Benjamin Wahl; Olga Schulz; Matthias Hardtke-Wolenski; Angela Schippers; Norbert Wagner; Werner Müller; Tim Sparwasser; Reinhold Förster; Oliver Pabst
Journal:  Immunity       Date:  2011-02-17       Impact factor: 31.745

4.  Malt1 blocks IL-1β production by macrophages in vitro and limits dextran sodium sulfate-induced intestinal inflammation in vivo.

Authors:  Mahdis Monajemi; Yvonne C F Pang; Saelin Bjornson; Susan C Menzies; Nico van Rooijen; Laura M Sly
Journal:  J Leukoc Biol       Date:  2018-06-14       Impact factor: 4.962

5.  MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Authors:  Linda R Klei; Dong Hu; Robert Panek; Danielle N Alfano; Rachel E Bridwell; Kelly M Bailey; Katherine I Oravecz-Wilson; Vincent J Concel; Emily M Hess; Matthew Van Beek; Phillip C Delekta; Shufang Gu; Simon C Watkins; Adrian T Ting; Peter J Gough; Kevin P Foley; John Bertin; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Cell Rep       Date:  2016-09-27       Impact factor: 9.423

6.  Selective MALT1 paracaspase inhibition does not block TNF-α production downstream of TLR4 in myeloid cells.

Authors:  Adeline Unterreiner; Natacha Stoehr; Christine Huppertz; Thomas Calzascia; Christopher J Farady; Frédéric Bornancin
Journal:  Immunol Lett       Date:  2017-10-24       Impact factor: 3.685

7.  A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency.

Authors:  Haifa H Jabara; Toshiro Ohsumi; Janet Chou; Michel J Massaad; Halli Benson; Andre Megarbane; Eliane Chouery; Raymond Mikhael; Oliver Gorka; Andreas Gewies; Pierre Portales; Toshinori Nakayama; Hiroyuki Hosokawa; Patrick Revy; Henry Herrod; Francoise Le Deist; Gerard Lefranc; Jürgen Ruland; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2013-05-31       Impact factor: 10.793

8.  Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.

Authors:  Marc Rosenbaum; Andreas Gewies; Konstanze Pechloff; Christoph Heuser; Thomas Engleitner; Torben Gehring; Lara Hartjes; Sabrina Krebs; Daniel Krappmann; Mark Kriegsmann; Wilko Weichert; Roland Rad; Christian Kurts; Jürgen Ruland
Journal:  Nat Commun       Date:  2019-05-28       Impact factor: 14.919

9.  Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo.

Authors:  Mahesh Yadav; Cedric Louvet; Dan Davini; James M Gardner; Marc Martinez-Llordella; Samantha Bailey-Bucktrout; Bryan A Anthony; Francis M Sverdrup; Richard Head; Daniel J Kuster; Peter Ruminski; David Weiss; David Von Schack; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2012-09-10       Impact factor: 14.307

Review 10.  Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.

Authors:  Mélanie Juilland; Margot Thome
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

View more
  7 in total

1.  Progressive B cell depletion in human MALT1 deficiency.

Authors:  Motoshi Sonoda; Masataka Ishimura; Katsuhide Eguchi; Yutaro Yada; Nina Lenhartová; Akira Shiraishi; Tamami Tanaka; Yasunari Sakai; Shouichi Ohga
Journal:  Clin Exp Immunol       Date:  2021-10-07       Impact factor: 4.330

2.  MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.

Authors:  Jie Yuan; Lei Xiang; Feng Wang; Lin Zhang; Gaozhan Liu; Xiuli Chang; Anbing Zhang; Ying Tao
Journal:  J Clin Lab Anal       Date:  2022-05-27       Impact factor: 3.124

Review 3.  CARD11 signaling in regulatory T cell development and function.

Authors:  Nicole M Carter; Joel L Pomerantz
Journal:  Adv Biol Regul       Date:  2022-02-26

4.  MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.

Authors:  Jia-Ying Lloyd Lee; Prasanna Ekambaram; Neil M Carleton; Dong Hu; Linda R Klei; Zongyou Cai; Max I Myers; Nathaniel E Hubel; Lidija Covic; Sameer Agnihotri; Daniel Krappmann; Frédéric Bornancin; Adrian V Lee; Steffi Oesterreich; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

5.  Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.

Authors:  Kea Martin; Ursula Junker; Elaine Tritto; Esther Sutter; Tina Rubic-Schneider; Hannah Morgan; Satoru Niwa; Jianping Li; Achim Schlapbach; Dana Walker; Marc Bigaud; Christian Beerli; Amanda Littlewood-Evans; Bettina Rudolph; Marc Laisney; David Ledieu; Karen Beltz; Jean Quancard; Frédéric Bornancin; Natasa Zamurovic Ribrioux; Thomas Calzascia
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

6.  Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.

Authors:  Zhigang Wu; Yingyan Bi
Journal:  J Clin Lab Anal       Date:  2022-01-08       Impact factor: 2.352

7.  A comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation.

Authors:  Fengjiao Wang; Jiahuan He; Siqi Liu; Ai Gao; Liu Yang; Guohuan Sun; Wanqiu Ding; Chuan-Yun Li; Fanglin Gou; Manman He; Fang Wang; Xiaoshuang Wang; Xiangnan Zhao; Ping Zhu; Sha Hao; Yanni Ma; Hui Cheng; Jia Yu; Tao Cheng
Journal:  Blood       Date:  2021-11-18       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.